3 recruiting, 2 completed. 3 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Completed 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow CellCentric Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma InoPd, Investigator's choice of SAT - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 3 | Recruiting | CellCentric Ltd. | 450 | 2026-08-01 | 2026-08-19 |
| Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Inobrodib, Pomalidomide, Dexamethasone - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Recruiting | CellCentric Ltd. | 100 | 2026-01-22 | 2026-09-21 |
| PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma Patient Interview - Multiple Myeloma | Completed | The Christie NHS Foundation Trust | 9 | 2024-04-05 | 2026-05-08 | |
| Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies CCS1477, Pomalidomide, Dexamethasone - Haematological Malignancy, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | CellCentric Ltd. | 250 | 2019-08-09 | 2026-06-24 |
| Study to Evaluate CCS1477 in Advanced Tumours CCS1477, Abiraterone acetate, Enzalutamide - Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Completed | CellCentric Ltd. | 219 | 2018-07-23 | 2026-09-25 |
Multiple Myeloma (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Hematologic Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Peripheral (1)
CCS1477 (4) · Dexamethasone (3) · pomalidomide (3) · daratumumab (2) · Abiraterone Acetate (1) · Azacitidine (1) · Bortezomib (1) · Lenalidomide (1) · atezolizumab (1) · carfilzomib (1) · darolutamide (1) · elotuzumab (1) · enzalutamide (1) · ixazomib (1) · olaparib (1)
United Kingdom (4) · United States (4) · France (2) · Spain (2) · Sweden (2) · Netherlands (1)
Johann de Bono, MD (1) · Naseer Qayum (1) · Sally Taylor, PhD (1) · Tim Somervaille (1)